Clinical significance of Mena and Her-2 expression in breast cancer

被引:0
作者
Du, J. W. [1 ]
Xu, K. Y. [1 ]
Fang, L. Y. [1 ]
Qi, X. L. [1 ]
机构
[1] Anhui Univ Sci & Technol, Sch Med, Huainan City 232001, Anhui, Peoples R China
关键词
Breast cancer; Mena; Her-2; Immunohistochemistry; Clinicopathological parameter; HIGH-RISK;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to determine the expression patterns of Mena and Her-2 in breast cancer tissues and to explore their clinical significance and correlation with clinicopathological parameters. Methods: The expression of Mena and Her-2 was detected in 40 breast cancer tissues and 14 normal breast tissues by immunohistochemistry, and the relationship of Mena and Her-2 expression with clinicopathological parameters was analyzed. Results: Both Mena (70%) and Her-2 (40%) were more commonly expressed in breast cancer than in normal breast tissue (7.1%, 0%, respectively; p < 0.05); further, Mena and Her-2 expression in breast cancer were positively correlated (r = 0.530, p < 0.05). In comparing expression with clinicopathological parameters of tumor samples, Mena and Her-2 were both associated with axillary lymph node metastasis and TNM stage (p < 0.05), but not with patient age or pathological type. Conclusions: Mena and Her-2 are related to the malignancy degree and metastasis of breast cancer, and thus may play a coordinating role in the occurrence and progression of breast cancer.
引用
收藏
页码:455 / 458
页数:4
相关论文
共 16 条
[1]   Breast cancer incidence and mortality trends in 16 European countries [J].
Botha, JL ;
Bray, F ;
Sankila, R ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) :1718-1729
[2]   HER-2 Signaling and Inhibition in Breast Cancer [J].
Browne, B. C. ;
O'Brien, N. ;
Duffy, M. J. ;
Crown, J. ;
O'Donovan, N. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (03) :419-438
[3]   Breast cancer statistics, 2011 [J].
DeSantis, Carol ;
Siegel, Rebecca ;
Bandi, Priti ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (06) :409-418
[4]   The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors [J].
Di Modugno, F ;
Mottolese, M ;
Di Benedetto, A ;
Conidi, A ;
Novelli, F ;
Perracchio, L ;
Venturo, I ;
Botti, C ;
Jager, E ;
Santoni, A ;
Natali, PG ;
Nisticò, P .
CLINICAL CANCER RESEARCH, 2006, 12 (05) :1470-1478
[5]   Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility and deficits in actin remodeling [J].
Hoffman, LM ;
Jensen, CC ;
Kloeker, S ;
Wang, CLA ;
Yoshigi, M ;
Beckerle, MC .
JOURNAL OF CELL BIOLOGY, 2006, 172 (05) :771-782
[6]   Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients [J].
Kröger, N ;
Milde-Langosch, K ;
Riethdorf, S ;
Schmoor, C ;
Schumacher, M ;
Zander, AR ;
Löning, T .
CLINICAL CANCER RESEARCH, 2006, 12 (01) :159-168
[7]   Function and regulation of Ena/VASP proteins [J].
Kwiatkowski, AV ;
Gertler, FB ;
Loureiro, JJ .
TRENDS IN CELL BIOLOGY, 2003, 13 (07) :386-392
[8]  
Liu Bing-bing, 2008, Chinese Journal of Pathology, V37, P266
[9]  
Long N, 2010, ASIAN PAC J CANCER P, V11, P107
[10]  
Mao Jie, 2005, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V30, P312